Ambrx is a startup based in the United States, most recent round Acquired, 3 tracked investors.
Based in the United States, Ambrx is a startup founded in 2003. Ambrx has been acquired. Brouky records 3 investors associated with the company.
Ambrx is a clinical-stage biopharmaceutical company focused on discovering and developing next-generation antibody-drug conjugates (ADCs) using its proprietary expanded genetic code technology platform.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.